A newborn boy died within a day of birth after an undetected herpes simplex virus (HSV), passed from his asymptomatic mother, ...

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) ...

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free survival in CSCC in the adjuvant setting, reducing the risk of ...

As rates of a little-known 'taboo' cancer surge across the US, especially among older women, leading oncologists reveal the ...

GLOBAL RELEASE - NOT INTENDED FOR UK MEDIA LEO Pharma A/S, a global leader in medical dermatology, today announced positive topline key results from the 32-week analysis of the Phase 3b ADHAND trial ...